Drug Trial Radar · NCT03900442
Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort
Last checked: Nov 19, 2026Latest source record: Sep 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Sep 1, 2019
Primary completion
Jul 31, 2025
Study completion Aug 8, 2025
Sponsor
- Lead sponsor
- Prescient Therapeutics, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, non-randomized study to evaluate the PD, PK, and safety of 500 to 2000 mg/m2 PTX-100 in patients with advanced malignancies. PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles unless toxicity is observed. Dose escalation is complete and the expansion is open and actively recruiting PTCL patients.
Conditions
- Advanced Cancer
- PTCL
Interventions
PTX-100Drug
Doses of 500 to 2000 mg/m2 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigate the time- and dose-dependent PD of multiple doses of PTX-100 in patients with advanced malignancies (RAP-1)Time frame: One Cycle (cycle = 14 days)
- Investigate the time- and dose-dependent PD of multiple doses of PTX-100 in patients with advanced malignancies (PD endpoints)Time frame: One Cycle (cycle = 14 days)
- Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (cmax)Time frame: One Cycle (cycle = 14 days)
- Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (Tmax)Time frame: One Cycle (cycle = 14 days)
- Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (half life)Time frame: One Cycle (cycle = 14 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Epworth Healthcare
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.